Ionty

Doi: 10.1111/cen.70049

1. Confirm hyponatremia (Serum Na < 135 mEq/l and Serum Osmolality < 275 mOsm/kg)
2. Asses ECF Volume Status (Clinically or via CVP, BUN/Cr, Hct): Hypovolemia? Euvolemia?
3. Measure urine and blood uric acid, urine and blood phosphate, and urine and blood creatine. Calculate fractional excretion of uric acid (FEurate) and phosphate (FEPO4).
4. Correct hyponatremia (saline or fluid restriction). Re-check FEurate and FEPO4
5. FEurate remains > 10 % (& FEPO4 high) => confirms CSWS. FEurate normalizes (& FEPO4 normalizes) => confirms SIADH.

BNP is variable.

• Normal FEurate (4–11%) during hyponatremia → suggests reset osmostat (a subtype of SIADH where the osmostat is set to a lower threshold but tubular function is normal). [3-4]
• Low FEurate (<4%) → suggests volume depletion from extrarenal losses (e.g., GI losses) or Addison's disease. [2-3]
• High FEurate (>11%) → narrows the differential to SIADH vs. C/RSW, and the next step is required. [1-2]

https://pubmed.ncbi.nlm.nih.gov/41058069

1. Value of Fractional Uric Acid Excretion in Differential Diagnosis of Hyponatremic Patients on Diuretics. The Journal of Clinical Endocrinology and Metabolism. 2008. Fenske W, Störk S, Koschker AC, et al.
2. Identifying Different Causes of Hyponatremia With Fractional Excretion of Uric Acid. The American Journal of the Medical Sciences. 2016. Imbriano LJ, Mattana J, Drakakis J, Maesaka JK.Case
3. Determining Fractional Urate Excretion Rates in Hyponatremic Conditions and Improved Methods to Distinguish Cerebral/­Renal Salt Wasting From the Syndrome of Inappropriate Secretion of Antidiuretic Hormone. Frontiers in Medicine. 2018. Maesaka JK, Imbriano LJ, Miyawaki N.
4. Differentiating Syndrome of Inappropriate ADH, Reset Osmostat, Cerebral/­Renal Salt Wasting Using Fractional Urate Excretion.

Journal of Pediatric Endocrinology & Metabolism : JPEM. 2021. Assadi F, Mazaheri M.Case

1. New Approach to Hyponatremia: High Prevalence of Cerebral/­Renal Salt Wasting, Identification of Natriuretic Protein That Causes Salt Wasting.

Journal of Clinical Medicine. 2022. Maesaka JK, Imbriano LJ, Grant C, Miyawaki N.Review

1. Diagnosis and Management of Hyponatremia: A Review.

The Journal of the American Medical Association. 2022. Adrogué HJ, Tucker BM, Madias NE.Review

1. Is It Cerebral or Renal Salt Wasting?. Kidney International. 2009. Maesaka JK, Imbriano LJ, Ali NM, Ilamathi E.Review
2. Diagnostic Utility of Fractional Excretion of Urate, Urinary Phosphate and Brain Natriuretic Peptide in Distinguishing Cerebral/­Renal Salt Wasting From SIADH in Neurologically Ill Children: A Systematic Review. Clinical Endocrinology. 2025. Assadi F.Review

Uric acid is freely filtered at the glomerulus, and approximately 90% is reabsorbed in the proximal tubule via transporters such as URAT1 and GLUT9.

In SIADH, at least three factors converge to suppress this proximal reabsorption and raise FEurate (normal 4–11%) to typically >12%:

• Mild volume expansion. SIADH causes water retention and subclinical expansion of the effective arterial blood volume. Volume expansion suppresses proximal tubular reabsorption broadly — including urate reabsorption — through reduced peritubular oncotic pressure and possibly circulating natriuretic/inhibitory factors. Classic animal studies demonstrated that extracellular fluid volume expansion reduces net proximal tubular urate reabsorption by ~37%.
• Hyponatremia itself. Interestingly, volume expansion alone does not fully explain the degree of uricosuria seen in SIADH. Decaux et al. showed that infusing 2 L of isotonic saline in normonatremic volunteers produced a similar degree of volume expansion (as estimated by plasma protein dilution) but raised FEurate to only ~9%, compared with ~17% in SIADH patients. Furthermore, SIADH patients with only mild water retention (~1 L) still had markedly elevated FEurate, suggesting that chronic hyponatremia per se contributes to impaired proximal urate reabsorption through a mechanism that is not fully elucidated.
• V1 receptor stimulation by ADH. ADH acts on both V1 and V2 receptors. Decaux et al. demonstrated that dDAVP-induced hyponatremia (which stimulates only V2 receptors) did not significantly increase urate clearance, whereas endogenous ADH excess in SIADH (stimulating both V1 and V2 receptors) markedly increased it. Administration of a V1 agonist to a patient with dDAVP-induced hyponatremia rapidly increased urate clearance, confirming that V1 receptor stimulation directly contributes to decreased tubular urate reabsorption.

Why FE of urate normalizes after correction in SIADH: When hyponatremia is corrected (by water restriction or hypertonic saline), all three drivers are reversed simultaneously:

• The mild volume expansion resolves as free water is excreted, restoring normal peritubular hemodynamics and proximal tubular reabsorptive capacity.
• The hyponatremia itself resolves, removing its independent suppressive effect on urate reabsorption.
• ADH secretion becomes appropriately suppressed once serum osmolality normalizes, eliminating the V1-mediated uricosuric effect.

With these stimuli removed, proximal tubular urate reabsorption returns to normal, and FEurate normalizes to <11%.

Physical examination has low sensitivity (50–70%) and low specificity (30–50%) for assessing volume status in hyponatremia, using response to saline as the reference standard. https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2022.11176?utm_source=openevidence&utm_medium=referral

IVC ultrasound and multi-organ POCUS (lung, cardiac, IVC, VExUS) have been studied as adjuncts to volume assessment in hyponatremia, but their utility for detecting the subtle volume expansion of SIADH is limited.

Laboratory Markers — The Most Useful Indirect Approach: Rather than directly measuring the volume expansion, laboratory markers that reflect its downstream consequences are the most practical tools:

• Low serum uric acid (<4 mg/dL) — present in ~70% of SIADH patients, reflecting increased renal urate clearance from volume expansion and V1 stimulation (as discussed previously). This is more specific for SIADH than for salt depletion, where low uric acid is seen in only ~40%.
• Low BUN — dilutional effect plus increased urea clearance from volume expansion. Typically low in SIADH, though less specific in elderly patients with lower urea generation.
• Low-normal serum albumin / low plasma protein — hemodilution from water retention. Decaux et al. used plasma protein concentration as a surrogate for estimating the degree of volume expansion in their studies.
• Low anion gap — dilution of unmeasured anions, with nearly normal total CO₂ and potassium (despite dilution). This pattern is relatively characteristic of SIADH.
• Elevated ANP/BNP — Plasma ANP is elevated up to 6-fold in SIADH patients compared to normals, reflecting atrial stretch from mild volume expansion. ANP levels normalize with water restriction and correction of hyponatremia, confirming the volume-dependent mechanism. However, ANP/BNP levels overlap considerably between SIADH and C/RSW and cannot reliably distinguish between them.
• Copeptin — has limited diagnostic value in SIADH specifically. Copeptin levels overlap widely between SIADH and other causes of hyponatremia, and its broad use as a diagnostic marker in hyponatremia is not recommended. The copeptin-to-urinary sodium ratio may help identify preserved extracellular fluid volume (AUC improvement over urine sodium alone), but this is more useful for distinguishing SIADH from hypovolemic states than for quantifying the degree of expansion.

Escape from antidiuresis" is a critical adaptive mechanism in SIADH that limits the degree of water retention and prevents overt edema formation despite persistently elevated vasopressin levels. This phenomenon explains why patients with chronic SIADH reach a new steady state with stable (though low) serum sodium rather than progressively worsening hyponatremia and volume overload.

The Mechanism of Vasopressin Escape: After the initial phase of water retention in SIADH, the kidney develops partial resistance to vasopressin's antidiuretic effect, allowing increased water excretion despite continued high circulating AVP. This occurs through multiple converging mechanisms:

1. Downregulation of aquaporin-2 (AQP2) water channels. The primary mechanism is loss of AQP2 expression in the collecting duct despite persistent V2 receptor stimulation by vasopressin.

[1-2] Single-tubule RNA-seq studies in a rat SIADH model revealed that vasopressin escape begins with a fall in Aqp2 gene expression starting on Day 1 of water loading, mediated by activation of transforming growth factor-β (TGF-β) signaling and a partial epithelial-to-mesenchymal transition in collecting duct principal cells. [1] This is followed by Notch signaling activation and cell cycle arrest at G2/M, ultimately resulting in virtually complete loss of AQP2 protein.

1. ANP-mediated antagonism of vasopressin action. The mild volume expansion (1.5–3 L) triggers atrial stretch and ANP secretion, which rises 6-fold above normal in SIADH patients. ANP antagonizes vasopressin through multiple mechanisms:
2. Direct inhibition of AQP2 function: ANP, acting via cGMP and protein kinase G (PKG), reduces vasopressin-induced phosphorylation of AQP2 at serine-256 and promotes AQP2 retrieval from the apical membrane back into the cytosol, thereby reducing water permeability.
3. Inhibition of sodium reabsorption: ANP blocks sodium reabsorption in the collecting duct (particularly the conductive sodium channel in the inner medullary collecting duct), which reduces the osmotic gradient for water reabsorption.
4. Increased glomerular filtration: ANP dilates afferent arterioles and constricts efferent arterioles, increasing glomerular capillary pressure and filtration rate, which promotes natriuresis and water excretion.

Importantly, plasma ANP levels normalize when hyponatremia is corrected by water restriction, confirming that ANP secretion is driven by the volume expansion itself.

1. Natriuresis limits further volume expansion. The combination of ANP secretion, suppressed aldosterone, and increased distal sodium delivery (from volume expansion-mediated suppression of proximal reabsorption) produces natriuresis — typically urine sodium >40 mEq/L despite hyponatremia. This sodium loss limits further extracellular fluid expansion and prevents progression to overt edema.

Why Edema Does Not Develop: The escape phenomenon establishes a new steady state where:

• Water intake equals water output (despite impaired free water excretion)
• Sodium balance is maintained (natriuresis matches intake)
• Total body water is increased by only 1.5–3 L, distributed across all compartments
• Extracellular volume expansion is modest (~10–15%), below the threshold for clinically detectable edema (~3–5 L excess)

This contrasts sharply with conditions like heart failure or cirrhosis, where escape does not occur because the persistent reduction in effective arterial blood volume continuously stimulates both vasopressin and the renin-angiotensin-aldosterone system, leading to progressive sodium and water retention and overt edema.

Clinical Implications: The escape phenomenon has important diagnostic and therapeutic implications:

• Diagnostic: The presence of natriuresis (urine Na >40 mEq/L) in a hyponatremic patient without edema supports SIADH, as it reflects the escaped state. However, this can be misleading early in the course before escape has occurred.
• Therapeutic: Escape limits the effectiveness of fluid restriction alone in chronic SIADH — approximately 50% of patients fail to respond adequately to fluid restriction, necessitating second-line therapies such as urea, vaptans, or SGLT2 inhibitors.
• Prognostic: The ability to escape prevents life-threatening volume overload in most SIADH cases, but the persistent hyponatremia itself remains clinically significant due to neurological and other complications.